Gold Intraday: More Upside Potential

On Monday, spot gold gained 0.4% to $1,817.7, the highest level since September 2011...

Gold 4

On Monday, AstraZeneca, Pfizer and BioNTech released promising phase 1/2 Covid-19 vaccine trial results and are progressing to larger trials. On the other hand, it is reported that U.S. Senate Majority Leader Mitch McConnell and House Minority Leader Kevin McCarthy met with President Donald Trump to discuss the Republican's proposed stimulus bill, which is expected to be released this week.


Spot gold gained 0.4% to $1,817.7, the highest level since September 2011. Despite the fact that vaccine's development should be negative to gold, commodity prices were lifted by expansionary fiscal policy, as spot silver jumped 3.0% to $19.90.


From a technical point of view, spot gold is gaining traction as shown on the 1-hour chart. Currently, it remains trading within a bullish channel drawn from mid-June and has broken above its recent consolidation range. Bullish investors might consider $1,804 as the nearest intraday support level, with prices trending test the next resistances at $1,826 and $1,835. Alternatively, a break below $1,804 might trigger a pull-back to the next support at $1,794.


Source: TradingView, Gain Capital

More from Gold

From time to time, GAIN Capital Australia Pty Ltd (“we”, “our”) website may contain links to other sites and/or resources provided by third parties. These links and/or resources are provided for your information only and we have no control over the contents of those materials, and in no way endorse their content. Any analysis, opinion, commentary or research-based material on our website is for information and educational purposes only and is not, in any circumstances, intended to be an offer, recommendation or solicitation to buy or sell. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. No representation or warranty is made, express or implied, that the materials on our website are complete or accurate. We are not under any obligation to update any such material.

As such, we (and/or our associated companies) will not be responsible or liable for any loss or damage incurred by you or any third party arising out of, or in connection with, any use of the information on our website (other than with regards to any duty or liability that we are unable to limit or exclude by law or under the applicable regulatory system) and any such liability is hereby expressly disclaimed.